Dietary nitrate prevents progression of carotid subclinical atherosclerosis through blood pressure-independent mechanisms in patients with or at risk of type 2 diabetes mellitus

Franca Morselli¹,²,⁶ | Luca Faconti¹,⁶ | Charlotte E. Mills³,⁴,⁶ | Steven Morant⁵ | Philip J. Chowienczyk¹,³,⁶ | Joshua Au Yeung¹,⁶ | Alessandro Cavarape² | J. Kennedy Cruickshank³,⁶ | Andrew J. Webb¹,⁶

¹Department of Clinical Pharmacology, King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, UK
²Dipartimento di Area Medica, Clinica Medica, Universita’ degli Studi di Udine, Udine, Italy
³King’s College London, Department of Nutritional Sciences, School of Life Course Sciences, London, UK
⁴Department of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, Reading, UK
⁵Medicines Monitoring Unit (MEMO), University of Dundee, UK
⁶Biomedical Research Centre, Clinical Research Facility, 4th Floor, North Wing, St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Correspondence
Dr Andrew J. Webb, Senior Lecturer in Cardiovascular Clinical Pharmacology, Department of Clinical Pharmacology, King’s College London, St Thomas’ Hospital, London, SE1 7EH, UK.
Email: andrew.1.webb@kcl.ac.uk

Funding information
Fukuda Denshi, Tokyo, Japan

Aims: To test if 6 months’ intervention with dietary nitrate and spironolactone could affect carotid subclinical atherosclerosis and stiffness, respectively, vs. placebo/doxazosin, to control for blood pressure (BP).

Methods: A subgroup of participants in our double-blind, randomized-controlled, factorial VaSera trial had carotid imaging. Patients with hypertension and with/at risk of type 2 diabetes were randomized to active nitrate-containing beetroot juice or placebo nitrate-depleted juice, and spironolactone or doxazosin. Vascular ultrasound for carotid diameter (CD, mm) and intima–media thickness (CIMT, mm) was performed at baseline, 3- and 6-months. Carotid local stiffness (CS, m/s) was estimated from aortic pulse pressure (Arteriograph) and carotid lumen area. Data were analysed by modified intention to treat and using mixed-model effect, adjusted for confounders.

Results: In total, 93 subjects had a baseline evaluation and 86% had follow-up data. No statistical interactions occurred between the juice and drug arms and BP was similar between the juices and between the drugs. Nitrate-containing vs. placebo juice significantly lowered CIMT (−0.06 [95% confidence interval −0.12, −0.01], P = .034), an overall difference of ~8% relative to baseline; but had no effect on CD or CS. Doxazosin appeared to reduce CS from baseline (−0.34 [−0.62, −0.06]) however, no difference was detected vs. spironolactone (−0.15 [−0.46, 0.16]). No differences were detected between spironolactone or doxazosin on CIMT and CD.

Conclusions: Our results show that 6 months’ intervention with dietary nitrate influences vascular remodelling, but not carotid stiffness or diameter. Neither spironolactone nor doxazosin had a BP-independent effect on carotid structure and function.
INTRODUCTION

Patients with type 2 diabetes (T2DM) are at increased risk of coronary heart disease, ischaemic stroke and vascular deaths. According to current guidelines, evaluation of cardiovascular risk in asymptomatic patients with T2DM should include the assessment of atherosclerotic burden. Although less powerful than coronary artery calcium screening for risk stratification, carotid intima-media thickness (CIMT) has been used as a widely available, simple and noninvasive marker of subclinical atherosclerosis. Also, some earlier studies suggested that CIMT may be a better tool than coronary artery calcium for predicting stroke, and it has been associated with coronary heart disease. As a measure of arterial wall thickness, an increased CIMT is considered to represent a quantitative expression of atherosclerotic burden and endothelial dysfunction.

Key steps in the atherogenic process include a decline in nitric oxide (NO) synthesis, increased reactive oxygen species production, diminished NO bioavailability and endothelial dysfunction. Dietary nitrate, as found in green leafy vegetables and beetroot, is a source of NO via the nitrate (NO3)-nitrite (NO2)-NO pathway and confers several beneficial actions on the cardiovascular system. Studies in humans show that provision of dietary nitrate may enhance endothelial function, and suppresses microvascular inflammation.

With respect to atherogenesis, studies in animals show that nitrate/nitrite may limit the development of intimal hyperplasia and smooth muscle cell proliferation, vascular ageing and atherosclerosis. Alef et al., found that sodium nitrite (24-h oral supplementation, a single intraperitoneal injection or via inhalation), limited intimal hyperplasia and smooth muscle cell proliferation following balloon injury of the rat carotid artery, whereas a low nitrate/nitrite diet increased intimal hyperplasia; notably, this could be reversed by the late introduction of nitrite. Studies performed in mice found mixed effects. Fourteen weeks’ supplementation with sodium nitrate had no effect on atherogenesis in low density lipoprotein receptor knockout mice (LDLr−/−). However, studies in apolipoprotein E knockout (ApoE−/−) mice have shown benefit. Ten weeks’ supplementation with low and moderate dose nitrate significantly improved endothelial function and atherosclerotic plaque composition in ApoE−/− mice fed a high-fat diet. Twelve weeks’ supplementation with dietary nitrate, caused reductions in macrophage accumulation and elevations in smooth muscle accumulation within atherosclerotic plaques of ApoE−/− mice, suggesting plaque stabilization, albeit without effect on total plaque area; effects were seen with normal chow and high fat diets. Eight weeks’ nitrate supplementation decreased atherosclerotic plaque area and inhibited vascular NADPH oxidase activity and oxidative stress in ApoE−/− mice fed a high fat diet.

Epidemiological data suggest that higher vegetable nitrate intake is associated with a lower CIMT and a lower risk of ischaemic cerebrovascular disease events and atherosclerotic vascular disease mortality in 1226 older women, and of new cases of cardiovascular disease-related complications over 15-years of follow-up in 5324 middle-aged women.

However, direct evidence in humans is scarce, with no randomized-controlled trial data reported to date on whether chronic supplementation with dietary nitrate affects carotid structure and stiffness. To our knowledge, there is only 1 study testing the effects of organic nitrates on CIMT: Sekiya et al. studied 42 patients with ischaemic heart disease randomly allocated to receive 3 months’ nicorandil (15 mg daily) or isosorbide dinitrate (ISDN; 40 mg daily). However, they found that ISDN increased/worsened CIMT, whilst nicorandil had no effect. In contrast to inorganic nitrate/nitrite, organic nitrates are associated with impairment of endothelial function and tolerance/loss of effect. Indeed, in that study, ISDN was found to worsen brachial artery flow mediated dilatation. This contrasts with antihypertensives, some of which have been extensively studied for their effects on CIMT. Mineralocorticoid receptor antagonists such as spironolactone have been shown to reduce the progression of CIMT over 2 years in nondiabetic patients on haemodialysis treated vs. placebo. In an uncontrolled study, eplerenone was found to improve CIMT in patients with primary aldosteronism over 6 and 12 months, though this was also associated with decreased blood pressure (BP). Over a prolonged period of 6 years, treatment of patients with primary aldosteronism with spironolactone had a similar significant effect on regression of CIMT as surgical treatment in patients with unilateral forms of primary aldosteronism, with no significant difference in BP between treatments. However, whether spironolactone confers specific effects on CIMT vs. other antihypertensives/independently of BP has not been tested.

Thus, in a subgroup of participants who took part in our VaSera trial, we performed serial carotid ultrasound scans to a priori evaluate the effect of dietary nitrate on carotid structure and function. We have already reported on the primary outcome of the main study, which was to assess whether 6 months’ intervention with dietary nitrate (vs. placebo), spironolactone (vs. doxazosin) or both (in a factorial design) could reduce arterial stiffness independently of BP, and the echocardiography subgroup findings.

METHODS

2.1 Study design and interventions

Among the patients with or at risk of T2DM who took part in the double-blind, randomized-controlled, factorial VaSera trial, a subpopulation had carotid ultrasound performed at baseline and
throughout the study as part of the cardiovascular measurements. Recruitment occurred between 2013 and 2015 at Guy’s and St. Thomas’ Hospitals, London, UK and surrounding areas. Inclusion criteria were age between 18 and 80 years; clinical diagnosis or at risk of T2DM (i.e. body mass index ≥27 kg/m², positive family history or glucose intolerance after 75 g challenge); capability of understanding and following the protocol. Exclusion criteria included interfering chronic illness, allergy/intolerance to either drug and/or beetroot, eGFR <45 mL/min, HbA1c > 11% (97 mmol/mol), pregnancy, breast feeding or atrial fibrillation. The study protocol was approved by South London Research Ethics Committee. After being consented at visit 1 (V1), participants were randomized at visit 2 (V2) to spironolactone (12.5 mg titrated to 25 mg, twice daily) or doxazosin (4 to 8 mg, twice daily) and dietary nitrate as Beet It beetroot juice (HeartBeet Ltd., Suffolk, UK, 4.5 mmol nitrate increased to 11.2 mmol once daily) or nitrate-free Beet It juice, a specific placebo, recommended to be taken daily with their existing treatment. Cardiovascular measures were performed at baseline (V2) and repeated at 3 months (visit 5, V5) and 6 months (visit 6, V6). The results for primary outcome, aortic arterial stiffness (measured using aortic pulse wave velocity [PWV]), central systolic pressure and augmentation are published elsewhere.28 Peripheral BP was measured according to guidelines,31 using a validated BP monitor (Intellisense 705IT, Omron, UK). Carotid ultrasound was performed by 2 expert operators, using a GE Vivid 7 Ultrasound System, and all images analysed by a single operator blinded to the intervention. Acquisitions respected the current recommendations for ultrasound evaluation of carotid arteries and common CIMT measurement.32,33 Carotid ultrasound image sequences were analysed using a highly automated method (Carotid Analyzer, Medical Imaging Application, LLC) for detection of near and far wall border, detection of near and far intima border, vessel diameter measurement, and CIMT measurement. Additional carotid parameters were calculated as follows: diameter distension (ΔD, mm), the difference between systolic and diastolic diameter; diameter distensibility (%), the diameter distension with respect to the diastolic diameter; area distension (mm²), the difference between systolic and diastolic carotid lumen area; diameter compliance (mm/mmHg), the diameter distension with respect to pulse pressure (which is the difference between central systolic [SBP] and diastolic [DBP] BP); cross sectional distensibility (CSD, %), the area distension with respect to the diastolic area; cross sectional compliance (mm²/mmHg), the area distension with respect to the pulse pressure; carotid stiffness, (CS, m/s), CSD coefficient corrected by blood density according to the Moens–Korteweg Equation.34 A visual summary of the timing of interventions and measurements is shown in Figure 1.

2.2 Statistical analysis

This was a prespecified/prospectively conducted, exploratory mechanistic part of the main VaSera trial, performed in a subgroup who had carotid imaging as part of their baseline and follow-up visits. The main trial was powered to detect a 20% (SD 8%) reduction in the primary outcome of PWVart with spironolactone, with minimum 80% power, at P < .05, requiring a sample size of 24 participants each arm, aiming for 30 to allow a 20% drop-out.35 The sample size was achieved in

![Figure 1](image-url)
the main trial, with 126 patients randomised, and 110 and 106 patients completing mid-point and end of trial, respectively. An effect on CIMT was a tertiary outcome. Our independent biostatistician conducted a modified intention-to-treat analyses using SAS (Version 9.3) and included in the analysis all randomised participants with at least 1 outcome data at any follow-up visit but planned to exclude any randomised patient who failed to received study medication or provided no follow-up for the primary outcome variable. The effect of the interventions was estimated using mixed-effects models, adjusted for sex, age, ethnicity (European, African-Caribbean, West African and others) and diagnosis of T2DM baseline value of the outcome as covariates. As per the statistical analysis plan, the models included an interaction term for drug × nitrate juice, which allowed us to test for nonadditive effects. If no statistical interactions are detected between the juice and drug arms, the data are presented separately. The models also included baseline covariates and the baseline value of the covariate being analysed. Our data are exploratory and hypothesis-generating, rather than confirmatory and hypothesis-testing, thus, results are presented as least-square mean changes from baseline and difference between drugs and juices, averaged over both follow up visits for each outcome, with 95% CIs; in accordance with the recent editorial, Statistical reporting of clinical pharmacology research.36 P-values are included when useful to demonstrate a statistically significant difference between interventions.

3 | RESULTS

Of the study participants, 93 had a baseline carotid ultrasound (V2) and 81 (86%) had follow-up imaging at V5 and V6 (Figure 2). No statistical interactions were detected between active beetroot or placebo juice arms and the spironolactone or doxazosin arms for any of the haemodynamic or carotid outcomes, so data are presented separately. Baseline characteristics of the study population are listed in Table 1. Haemodynamic and carotid parameters compared to baseline are summarised in Table 2.

SBP and DBP did not differ between nitrate-containing and nitrate-depleted juice or between spironolactone and doxazosin (Table 2).

Data confirming adherence to the beetroot juice arm in the main study are published by Mills et al.28 Baseline CIMT was similar across each intervention group, e.g. 0.72 mm in the placebo and 0.75 mm in the active juice group (Table 1). Compared to placebo juice, active nitrate-containing beetroot juice lowered CIMT (−0.06 mm [95% confidence interval −0.12, −0.01]; \( P = .034; \) Table 2, Figure 3); thus, representing a difference of ~8% relative to baseline. Compared to baseline, CIMT increased with the nitrate-depleted (0.05 mm [0.02, 0.09]; \( P = .005; \) Table 2, Figure 3A).

Compared to placebo juice, active nitrate-containing beetroot juice resulted in no differences in maximum or minimum carotid diameter (CD; Table 2; Figure 4), or the difference between systolic and diastolic carotid diameter \( \Delta D \), diameter compliance, distensibility, cross-sectional compliance or CSD, or CS (Table 2; Figure 5).

Compared to doxazosin, spironolactone had no effect on CIMT, CD or CS. CS was reduced from baseline with doxazosin (−0.34 mm [−0.62, −0.06]; \( P = .018 \)), but not with spironolactone (−0.15 mm [−0.46, 0.16]; Table 2).

4 | DISCUSSION

Our study shows that 6 months' dietary nitrate as beetroot juice reduces CIMT, a marker of subclinical atherosclerosis, compared to nitrate-depleted placebo juice. This effect was independent of BP.
which did not differ between nitrate-rich and placebo juice, in line with the results from the overall study. The absence of changes in which did not differ between nitrate-rich and placebo juice, in line alongside other measures to control risk factors for atheroscler.

The effects of dietary nitrate on BP are well-described, and there is growing interest around its role for the reduction of cardio-

BMM, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CIMT, carotid intima-media thickness; Max CD, maximum (systolic) carotid diameter; min CD, minimum (diastolic) carotid diameter; ΔD, difference between systolic and diastolic carotid diameter; DD, diameter distensibility; ΔA, difference between systolic and diastolic carotid lumen; DC, diameter compliance; CSD, cross sectional distensibility; CSC1, cross sectional compliance; CSDc, cross sectional distensibility coefficient; CS, carotid stiffness. SD, standard deviation

The effects of dietary nitrate on BP are well-described, and there is growing interest around its role for the reduction of cardiovascular risk. Our findings highlight the potential of dietary nitrate to decelerate the atherosclerotic process in a population at increased risk, and this is the first randomized, placebo-controlled clinical trial demonstrating such an effect in humans. As we described in the Introduction, thickening of the carotid intima-media on ultrasound is an early marker of atherosclerosis, and the early involvement of the intima in the atherogenic process is well-established. Also, diminished production and availability of NO are important factors in the earliest phases of atherogenesis. Thus, dietary nitrate might be useful to supply the endothelium with NO and prevent oxidative stress, alongside other measures to control risk factors for atherosclerosis. Indeed, as we described above, evidence of beneficial effects of long-term dietary nitrate on atherosclerosis has been previously reported from some, but not all studies performed in rats and Apo E−/− mice, and an association has been observed in epidemiological studies. The cohort study by Bondone et al. which included older Australian women aged 70−85 years, and without prevalent atherosclerotic vascular disease and/or diabetes, evaluated the nitrate intake from vegetables. Higher vegetable nitrate intake was associated with lower CIMT for each 1 standard deviation or 29 mg/d (i.e., ~0.5 mmol/d) increase in nitrate intake, CIMT was decreased (~0.012 mm, P = .006); this was associated with a 17% lower risk of 14.5-year ischaemic cerebrovascular events, and diminished atherosclerosis related mortality. In our study, the nitrate intake was ~7.5 mmol/d for 3 months, which was increased to ~11.2 mmol/d from 3−6 months and resulted in a decrease in CIMT of 0.06 mm (vs. nitrate-free Beet It juice) over 6 months. To our knowledge, our study provides the first randomized, placebo-controlled trial evidence for the potential favourable direct effect of dietary nitrate on CIMT, and in a population comprising high risk males as well as females. Very recently, a single-arm, open-label phase 2 proof of concept study by Hughan et al., showed that 12 weeks’ of

**TABLE 1** Baseline characteristics of the study population.

|                         | Doxazosin Placebo | Doxazosin Active | Spironolactone Placebo | Spironolactone Active |
|-------------------------|-------------------|------------------|------------------------|-----------------------|
| Patients                | n                 | n (%)            | n (%)                  | n (%)                 |
| Sex, female             | 22                | 17               | 21                     | 21                    |
| Type 2 diabetes         | 16 (73)           | 11 (65)          | 15 (71)                | 11 (52)               |
| Cardiovascular events   | 1 (5)             | 2 (12)           | 2 (10)                 | 2 (10)                |
| Smoker                  | 2 (9)             | 2 (12)           | 2 (12)                 | 1 (5)                 |
| Age (y)                 | Mean (SD) 59.1 (11.3) | 57.8 (14.6) | 57.4 (12.1) | 56.6 (15) |
| BMI (kg/m²)             | Mean (SD) 32.3 (5.8) | 32.6 (7.8) | 33.2 (5.7) | 31.6 (4.3) |
| SBP (mmHg)              | Mean (SD) 142.2 (20.74) | 130.6 (19.05) | 131.6 (14.08) | 141 (25.98) |
| DBP (mmHg)              | Mean (SD) 81.7 (13.3) | 75.4 (12.2) | 80.1 (11.2) | 83.1 (13.5) |
| CIMT (mm)               | Mean (SD) 0.72 (0.16) | 0.75 (0.18) | 0.71 (0.23) | 0.75 (0.14) |
| Max CD (mm)             | Mean (SD) 7.99 (1.07) | 7.99 (0.85) | 7.84 (1.22) | 8.11 (0.84) |
| Min CD (mm)             | Mean (SD) 7.43 (1.02) | 7.53 (0.80) | 7.31 (1.13) | 7.51 (0.84) |
| ΔD (mm)                 | Mean (SD) −0.28 (0.16) | −0.36 (0.13) | −0.31 (0.19) | −0.24 (0.09) |
| DD (%)                  | Mean (SD) 0.85 (0.16) | 0.77 (0.09) | 0.83 (0.14) | 0.89 (0.14) |
| ΔA (mm²/m²)             | Mean (SD) 0.8 (0.16) | 0.73 (0.13) | 0.76 (0.19) | 0.85 (0.14) |
| DC (mm/mmHg)            | Mean (SD) −1.95 (0.20) | −1.99 (0.16) | −2.01 (0.22) | −1.97 (0.13) |
| CSD (%)                 | Mean (SD) 1.17 (0.16) | 1.08 (0.09) | 1.15 (0.19) | 1.21 (0.14) |
| CSC1 (mm²/mmHg)         | Mean (SD) −0.88 (0.20) | −0.91 (0.16) | −0.94 (0.22) | −0.89 (0.13) |
| CSDc (kPa⁻¹ x 10⁻³)     | Mean (SD) −2.49 (0.20) | −2.55 (0.16) | −2.56 (0.42) | −2.52 (0.18) |
| CS (m/s)                | Mean (SD) 5.53 (1.35) | 5.91 (1.20) | 6.02 (1.43) | 5.74 (1.21) |
TABLE 2  Haemodynamic and carotid parameters (Model 2: fully-adjusted model for sex and age, plus ethnicity and diagnosis of diabetes).

|                      | Active juice | Placebo juice | Active vs. placebo | Spironolactone | Doxazosin | Spironolactone vs. doxazosin |
|----------------------|--------------|---------------|--------------------|-----------------|-----------|-----------------------------|
|                      | (n = 38)     | (n = 43)      | Active vs. placebo | Spironolactone  | (n = 42)  | (n = 39)                    |
| ΔSBP (mmHg)          | −7.59 (−10.7, −4.51) | −6.52 (−9.70, −3.34) | −1.08 (−5.56, 3.40) | −7.42 (−10.6, −4.28) | −6.69 (−9.79, −3.59) | −0.74 (−5.20, 3.73) |
| ΔDBP (mmHg)          | −5.05 (−6.80, −3.31) | −4.85 (−6.65, −3.05) | −0.21 (−2.74, 2.33) | −5.15 (−6.93, −3.38) | −4.75 (−6.50, −3.00) | −0.40 (−2.92, 2.11) |
| ΔCIMT (mm)           | −0.01 (−0.05, 0.03) | 0.05 (0.02, 0.09)  | −0.06 (−0.12, −0.00) | 0.05 (0.01, 0.09)  | 0.00 (−0.04, 0.04)  | 0.05 (−0.01, 0.11)  |
| Δmax CD (mm)         | −0.09 (−0.26, 0.07) | −0.13 (−0.29, 0.02) | 0.04 (−0.19, 0.27)  | −0.17 (−0.33, −0.01) | −0.06 (−0.22, 0.10) | −0.11 (−0.35, 0.12) |
| Δmin CD (mm)         | −0.10 (−0.26, 0.05) | −0.19 (−0.34, −0.05) | 0.09 (−0.13, 0.31)  | −0.17 (−0.32, −0.02) | −0.13 (−0.28, 0.03) | −0.04 (−0.27, 0.18) |
| Δ(ΔD) (mm) *         | 0.99 (0.91, 1.08)  | 1.08 (0.99, 1.17)  | 0.92 (0.82, 1.04)   | 0.99 (0.91, 1.08)  | 1.08 (0.99, 1.17)  | 0.92 (0.82, 1.04)   |
| ΔDD (%) *            | 1.01 (0.92, 1.10)  | 1.10 (1.01, 1.19)  | 0.92 (0.81, 1.04)   | 1.01 (0.93, 1.11)  | 1.09 (1.01, 1.19)  | 0.93 (0.82, 1.05)   |
| Δ(ΔA) (mm²) *        | 0.98 (0.90, 1.07)  | 1.06 (0.97, 1.15)  | 0.93 (0.82, 1.05)   | 0.97 (0.89, 1.07)  | 1.07 (0.98, 1.16)  | 0.91 (0.80, 1.04)   |
| ΔDC (mm/mmHg) *      | 1.03 (0.93, 1.14)  | 1.10 (1.01, 1.22)  | 0.93 (0.81, 1.08)   | 1.03 (0.92, 1.14)  | 1.11 (1.01, 1.22)  | 0.93 (0.80, 1.07)   |
| ΔCSD (%) *           | 1.01 (0.92, 1.11)  | 1.10 (1.01, 1.20)  | 0.91 (0.81, 1.04)   | 1.01 (0.93, 1.11)  | 1.10 (1.00, 1.20)  | 0.93 (0.81, 1.06)   |
| ΔCSC1 (mm²/mmHg) *   | 1.02 (0.92, 1.10)  | 1.08 (0.98, 1.20)  | 0.94 (0.81, 1.10)   | 1.01 (0.90, 1.13)  | 1.09 (0.98, 1.20)  | 0.92 (0.78, 1.07)   |
| ΔCSDc (kPa⁻¹ x 10⁻³) * | 1.04 (0.94, 1.16) | 1.14 (1.03, 1.26)  | 0.92 (0.79, 1.06)   | 1.05 (0.94, 1.17)  | 1.13 (1.02, 1.25)  | 0.93 (0.80, 1.08)   |
| ΔCS (m/s)            | −0.11 (−0.40, 0.18) | −0.38 (−0.66, −0.10) | 0.27 (−0.14, 0.68)  | −0.15 (−0.46, 0.16) | −0.34 (−0.62, −0.06) | 3.19 (−0.24, 0.62) |

Change from baseline, active nitrate-containing beetroot juice vs. placebo nitrate-depleted juice, and spironolactone vs. doxazosin. SBP, systolic blood pressure; DBP, diastolic blood pressure; CIMT, carotid intima-media thickness; Max CD, maximum (systolic) carotid diameter; min CD, minimum (diastolic) carotid diameter; ΔD, difference between systolic and diastolic carotid diameter; ΔA, difference between systolic and diastolic carotid lumen; ΔC, diameter compliance; CSD, cross sectional distensibility; CSC1, cross sectional compliance; CSDc, cross sectional distensibility coefficient; CS, carotid stiffness. The data presented are least squares mean (LSM) changes from baseline (or relative changes, indicated by *) and their 95% confidence intervals (CIs), estimated from a mixed-effects model and adjusted for sex and age, plus ethnicity and diagnosis of diabetes. Estimates that were significant at P < .05 in these models are highlighted in bold.
oral sodium nitrite (40 mg 3 times a day) reduced CIMT by 0.04 mm from 0.773 ± 0.02 mm at baseline to 0.730 ± 0.02 at 12 weeks ($P = .0054$) in 20 patients with hypertension and metabolic syndrome. This study provides valuable mechanistic support for an effect of nitrite on CIMT, albeit accompanied by a significant decrease in semi-recumbent SBP and DBP and a significant ~11% increase in resting conduit artery diameter (brachial) from 0.36 ± 0.02 mm to 0.40 ± 0.02 mm after 12 weeks of nitrite therapy ($P = .0009$); this is similar to the acute vasodilatory effect of systemically-infused nitrite we had previously observed. As commented above, our observed effect of dietary nitrate on CIMT was in the absence of changes in BP or carotid diameter.

Whilst not part of the main comparative analysis, inspection of the remaining data reveals that there was evidence of a decrease in CS from baseline with placebo juice and with doxazosin, (also, similar nonsignificant trends for nitrate-rich juice and for spironolactone). However, no difference was found between the juices, or between drugs, for CS reduction. We recently reported, as part of the main findings of this VaSera study, that doxazosin decreased arterial stiffness as aortic PWV. Similar to its effect on muscular arteries, doxazosin is likely to reduce vascular tone and arterial stiffness in larger elastic arteries, such as the aorta and its branches. Differences in measurement techniques between arterial stiffness (measured using PWV) and carotid stiffness (measured using echo-tracking) and sample size may account, at least in part, for the lack of a significant effect of doxazosin (vs. spironolactone) on CS. In addition, previous studies have shown that risk factors such as high BP and type 2 diabetes stiffen the aorta more than the carotid. Thus, the aortic response to doxazosin (PWV) might have been more evident than the carotid response (CS), in a population such as ours with these risk factors. Also, we have recently found that the relationship between circulating plasma nitrite concentration and pulse pressure, which is related to large artery stiffness, is more complex than we anticipated, albeit in an acute crossover study. Whilst active beetroot juice significantly decreased pulse pressure vs. placebo juice, addition of grapefruit juice, further decreased pulse pressure despite decreasing plasma nitrite concentration.

Overall, our results show that dietary nitrate influences vascular remodelling, probably acting on those layers of the vascular wall that are mainly involved in the atherogenic process. This might be due to the provision of an alternative source of NO, in the face of diminished NO production seen in the early stages of atheroma formation.

We acknowledge that current guidelines in Europe and the USA do not recommend routine CIMT evaluation as part of the cardiovascular risk assessment, and this is mainly due to conflicting results and lack of standardisation of measurements methods. CIMT remains an established marker of subclinical atherosclerosis, and further research is needed to clarify its role in the cardiovascular risk evaluation of asymptomatic individuals.

Whilst this was a well-controlled study (double blind placebo for nitrate) and the first trial of its kind for dietary nitrate—with 6 months’ intervention, there were several limitations. For example, CIMT, together with other carotid vascular parameters, were not the primary outcome of the VaSera trial. Also, a relatively small subsample of 81 patients had follow-up data. Thus, our analysis is exploratory, and our results require further confirmation from larger studies. We did not assess physical activity and we had decided in the original design of the study, that habitual diet, including dietary nitrate intake, would not be controlled for, as we wished to reflect a real-world situation, and thus this could also be viewed as a strength; this was intentionally a pragmatic trial. Instead, we measured plasma nitrate and nitrite concentrations in the main study and found that they were elevated in patients on active (nitrate-containing) vs. placebo (nitrate-depleted) beetroot juice, providing evidence of reasonable adherence and with an elevation above a variable background nitrate intake. Whilst food frequency questionnaires have some limitations, the development of a reference database for assessing dietary nitrate in vegetables, which can be used in conjunction with a food frequency questionnaire, provides a useful tool for future interventional studies.
**FIGURE 4** Effect of dietary nitrate as beetroot juice on carotid diameter (CD) measured by B-mode ultrasound. Change from baseline in maximum (A) and minimum (C) CD for active nitrate-rich juice and placebo nitrate-depleted juice. Overall effect of active juice vs. placebo juice on maximum (B) and minimum (D) CD. Data shown as least-square means with 95% confidence intervals.

**FIGURE 5** Effect of dietary nitrate as beetroot juice on carotid stiffness (CS) measured by B-mode ultrasound. (A) Change from baseline in CS for active nitrate-rich juice and placebo nitrate-depleted juice. (B) Overall effect of active juice vs. placebo juice on CS. Data shown as least-square means with 95% confidence intervals.
besides the observational/epidemiological studies. Also, we have recently found that environmental nitrogen dioxide, including from gas appliances such as gas cookers, increases plasma nitrite concentration and lowers SBP and DBP.29 Thus there is potential for confounding of the effect of dietary nitrate-derived circulating nitrite by nitrogen dioxide-derived circulating nitrite from atmospheric pollution and domestic gas appliances.

5 | CONCLUSION

CIMT was lower after 6 months of active beetroot juice intake compared to placebo juice. Other vascular parameters, such as carotid diameter and stiffness, did not differ between interventions. Thus, our results suggest that dietary nitrate might have a beneficial effect on intima-media remodelling, which is involved in atherogenesis, and thus represent a potential intervention to prevent or treat atherosclerosis.

ACKNOWLEDGEMENTS

The authors would like to thank the research nurses at Clinical Research Facility at St Thomas’ Hospital for their assistance in running the study, as well as the study participants. We also thank Karen McNeill for managing the blinding and randomization of the interventions, and Suzanne Barrett, who worked as research administrator. The work was funded by Fukuda Densi, Tokyo, Japan. We acknowledge internal infrastructure financial support from King’s College London British Heart Foundation Centre; National Institute for Health Research (NIHR), Clinical Research Facility at Guy’s & St Thomas’ NHS Foundation Trust, NIHR Biomedical Research Centre, based at Guy’s and St Thomas’ NHS Foundation Trust, and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

COMPETING INTERESTS

A.J.W. holds shares in HeartBeet Ltd, which receive a royalty from James White Drinks Ltd who manufacture the active nitrate-containing beetroot juice and placebo nitrate-depleted juice used in this study. The other authors have stated explicitly that there are no conflicts of interest in connection with this article. This work was funded by Fukuda Densi, Tokyo, Japan.

CONTRIBUTORS

A.J.W. and J.K.C both led the design of the VaSera trial, oversaw the data acquisition and analysis, and were involved in the interpretation of the results and revising the manuscript drafts. F.M. contributed to data acquisition, interpretation of the results and led drafting of the manuscript. L.F. and C. M were involved in research design, data acquisition and interpretation, and revised the manuscript drafts. S.V.M. led the data analysis and contributed to the manuscript drafts. P.C., J.A.Y. and A.C. were involved in the interpretation of the results and contributed to manuscript drafts. All authors approved the final version of the manuscript and have agreed accountability for the research.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Franca Morselli https://orcid.org/0000-0002-6186-4780
Luca Facanti https://orcid.org/0000-0002-1066-6899
Charlotte E. Mills https://orcid.org/0000-0002-8313-3700
Philip J. Chowienczyk https://orcid.org/0000-0003-4507-038X
J. Kennedy Cruickshank https://orcid.org/0000-0001-8126-1760
Andrew J. Webb https://orcid.org/0000-0002-8109-1877

REFERENCES

1. Folsom A, Kronmal R, Detrano R, et al. Coronary artery calcification compared with carotid intimamedia thickness in prediction of cardiovascular disease incidence: the Multi-Ethnic study of Atherosclerosis (MESA). Arch Intern Med. 2008;168(12):1333-1339. https://doi.org/10.1001/archinte.168.12.1333
2. Newman A, Naydeck B, Ives D, et al. Coronary artery calcium, carotid artery wall thickness and cardiovascular disease outcomes in adults 70 to 99 years old. Am J Cardiol. 2008;101(2):186-192. https://doi.org/10.1016/j.amjcard.2007.07.075
3. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD guidelines of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;255-323. https://doi.org/10.1093/eurheartj/ehz486
4. Malik S, Budoff MJ, Katz R, et al. Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes. Diabetes Care. 2011;34(10):2285-2290. https://doi.org/10.2337/dc11-0816
5. van Sloten TT, Stehouwer CDA. Carotid stiffness: a novel cerebrovascular disease risk factor. Pulse. 2016;4(1):24-27. https://doi.org/10.1159/000445354
6. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation. 2007;115(4):459-467. https://doi.org/10.1161/CIRCULATIONAHA.106.628875
7. Centurión OA. Carotid intima-media thickness as a cardiovascular risk factor and imaging pathway of atherosclerosis. Crit Pathw Cardiol. 2016;15(4):152-160. https://doi.org/10.1097/HPC.0000000000000087
8. Nezu T, Hosomi N, Aoki S, Matsumoto M. Carotid Intima-media thickness for atherosclerosis. J Atheroscler Thromb. 2016;23(1):18-31. https://doi.org/10.5551/jat.31989
9. Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovas Imaging. 2014;7(10):1025-1038. https://doi.org/10.1016/j.jcmg.2013.11.014
10. Förstermann U, Ni X, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713-735. https://doi.org/10.1161/CIRCRESAHA.116.309326
11. Khatri J, Mills CE, Maskell P, Odongerel C, Webb AJ. Is rocket science–why dietary nitrate is hard to ‘beet’! Part I: twists and turns in the realization of the nitrate-nitrite–NO pathway. Br J Clin Pharmacol. 2017;83(1):129-139. https://doi.org/10.1111/bcp.12913
12. Mills CE, Khatri J, Maskell P, Odongerel C, Webb AJ. Is rocket science–why dietary nitrate is hard to ‘beet’! Part II: further mechanisms and therapeutic potential of the nitrate-nitrite-NO pathway. Br J Clin Pharmacol. 2017;83(1):140-151. https://doi.org/10.1111/bcp.12918
13. Velmurugan S, Gan JM, Rathod KS, et al. Dietary nitrate improves vascular function in patients with hypercholesterolemia: A
randomized, double-blind, placebo-controlled study. Am J Clin Nutr. 2016;103(1):25-38. https://doi.org/10.3945/ajcn.115.116244

14. Rammos C, Hendgen-Cotta UB, Pohl J, et al. Modulation of circulating macrophage migration inhibitory factor in the elderly. Biomed Res Int. 2014;2014:1-8. https://doi.org/10.1155/2014/582586

15. Lidder S, Webb AJ. Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway. Br J Clin Pharmacol. 2013;75(3):677-696. https://doi.org/10.1111/j.1365-2125.2012.04420.x

16. Alef MJ, Vallabhaneni R, Carchman E, et al. Nitrite-generated NO circumvents dysregulated arginase/NO signaling to protect against intimal hyperplasia in Sprague-Dawley rats. J Clin Invest. 2011;121(4):1-11. https://doi.org/10.1172/JCI44079DS1

17. Marsch E, Theelen TL, Janssen BJA, et al. The effect of prolonged dietary nitrate supplementation on atherosclerosis development. Atherosclerosis. 2016;245:212-221. https://doi.org/10.1016/j.atherosclerosis.2015.11.031

18. Bakker JR, Bondonno NP, Gaspari TA, et al. Low dose dietary nitrate improves endothelial dysfunction and plaque stability in the ApoE–/– mouse fed a high fat diet. Free Radiol Biol Med. 2016;99:189-198. https://doi.org/10.1161/FREERADIOMI.116.0000000000C0

19. Khambata RS, Ghosh SM, Rathod KS, et al. Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque. Proc Nutr Acad Sci U S A. 2017;114(4):E550-E559. https://doi.org/10.1073/pnas.1613063114

20. Peng R, Luo M, Tian R, Lu N. Dietary nitrate attenuated endothelial dysfunction and atherosclerosis in apolipoprotein E knockout mice fed a high-fat diet: A critical role for NADPH oxidase. Arch Biochem Biophys. 2020;689:108453. https://doi.org/10.1016/j.abb.2020.108453

21. Bondonno CP, Blekkenhorst LC, Prince RL, et al. Association of Vegetable Nitrate Intake with Carotid Atherosclerosis and Ischemic Cerebrovascular Disease in Older Women. Stroke. 2017;48(7):1724-1729. https://doi.org/10.1161/STROKEAHA.117.016844

22. Blekkenhorst LC, Bondonno CP, Lewis JR, et al. Association of dietary nitrate with atherosclerotic vascular disease mortality: A prospective cohort study of older adult women. Am J Clin Nutr. 2017;106(1):207-216. https://doi.org/10.3945/ajcn.116.146761

23. Jackson JK, Patterson AJ, MacDonald-Wicks LK, et al. Vegetable nitrate intakes are associated with reduced self-reported cardiovascular-related complications within a representative sample of middle-aged Australian women, prospectively followed up for 15 years. Nutrients. 2019;11(2):1-19. https://doi.org/10.3390/nu11020240

24. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol. 2005;46(1):63-67. https://doi.org/10.1097/01.fjc. 0000162771.00174.a8

25. Vukusich A, Kunstmann S, Varella C, et al. A randomized, double-blind, placebo-controlled trial of spinoranolone on carotid intima-media thickness in nonobese hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8):1380-1387. https://doi.org/10.2215/CJN.09421209

26. Matsuda Y, Kawate H, Matsuoka C, et al. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. Endocr J. 2016;63(3):249-255. https://doi.org/10.1507/endocjr.EL15-0362

27. Holaj R, Rosa J, Zelinika T, et al. Long-term effect of speciﬁc treatment of primary aldosteronism on carotid intima-media thickness. J Hypertens. 2015;33(4):874-882. https://doi.org/10.1097/1HJH.0000000000000464

28. Mills CE, Govoni V, Faconti L, et al. A randomised, factorial trial to reduce arterial stiffness independently of blood pressure: Proof of concept? The VaSera trial testing dietary nitrate and spinoranolone. Br J Clin Pharmacol. 2020;86(5):891-902. https://doi.org/10.1111/bcp.14194

29. Mills CE, Govoni V, Faconti L, Casagrande ML, Morant SV, Webb AJ. Reducing arterial stiffness independently of blood pressure. JACC. 2017;70(13):1683-1684. https://doi.org/10.1016/j.jacc.2017.07.765

30. Faconti L, Mills CE, Govoni V, et al. Cardiac effects of 6 months’ dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial. Br J Clin Pharmacol. 2019;85(1):169-180. https://doi.org/10.1111/bcp.13783

31. BIHS. Measuring blood pressure using automated monitors, 2017. https://bihsoc.org/resources/bp-measurement/measure-blood-pressure/

32. Oates CP, Naylor AR, Hartsorne T, et al. Joint Recommendations for Reporting Carotid Ultrasound Investigations in the United Kingdom. Eur J Vasc Endovasc Surg. 2009;37(3):251-261. https://doi.org/10.1016/j.ejvs.2008.10.015

33. Simova I. Intima-media thickness: appropriate evaluation and proper measurement. E-Journal Cardiology Pract. 2015, [Online]. Available: 13(21). https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-13/Intima-media-thickness-Appropriate-evaluation-and-proper-measurement-described

34. Bruno RM, Cartoni G, Stea F, et al. Carotid and aortic stiffness in essential hypertension and their relation with target organ damage: The CATOD study. J Hypertens. 2017;35(2):310-318. https://doi.org/10.1097/HJH.000000000001167

35. Mills CE, Govoni V, Casagrande ML, Faconti L, Webb AJ, Cruickshank JK. Design and progress of a factorial trial testing the effect of spinoranolone and inorganic nitrate on arterial function in people at risk of or with type 2 diabetes ScienceDirect Design and progress of a factorial trial testing the effect of spinoranolacto. Artery Research. 2019;12:48-53.

36. Ring A, Schall R, Loke YK, Day S. Statistical reporting of clinical pharmacology research. Br J Clin Pharmacol. 2017;83(6):1159-1162. https://doi.org/10.1111/bcp.13254

37. Borgehi C, Tsiofis K, Agabiti-Rosei E, et al. Nutraceuticals and blood pressure control: A European Society of Hypertension position document. J Hypertens. 2020;38(9):799-812. https://doi.org/10.1097/JHJ.0000000000002353

38. Borgehi C, Cicero AFG. Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses. Br J Clin Pharmacol. 2017;83(1):163-171. https://doi.org/10.1111/bcp.12902

39. Bahadoran Z, Mirmiran P, Kabir A, Azizi F, Ghasemi A. The nitrate-independent blood pressure–lowering effect of beetroot juice: a systematic review and meta-analysis, Adv Nutr an Int Rev J. 2017;8(6): 830-838. https://doi.org/10.3945/an.117.016717

40. Jackson JK, Patterson AJ, MacDonald-Wicks LK, Oldmeadow C, McEvoy MA. The role of inorganic nitrate and nitrite in cardiovascular disease risk factors: A systematic review and meta-analysis of human evidence. Nutr Rev. 2018;76(5):348-371. https://doi.org/10.1093/nutrit/nuy005

41. Blekkenhorst LC, Bondonno CP, Lewis JR, et al. Cruciferous and total vegetable intakes are inversely associated with subclinical atherosclerosis in older adult women. J Am Heart Assoc. 2018;7(8):1-13. https://doi.org/10.1161/JAHA.117.008391

42. Hughan KS, Helbling NL, Anthony SJ, Delany J, Goodpaster BH, Gladwin M. Oral Sodium Nitrite Improves Insulin Sensitivity, Blood Pressure, and Arterial Thickening in Adults with Uncontrolled Hypertension and Metabolic Syndrome. Hypertension. 2020;67(6):874. https://doi.org/10.1161/HYPERTENSIONAHA.120.14930

43. Omar SA, Fok H, Tilgner KD, et al. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures.
44. Paini A, Boutouyrie P, Calvet D, Tropeano AI, Laloux B, Laurent S. Carotid and aortic stiffness determinants of discrepancies. Hypertension. 2006;47(3):371-376. https://doi.org/10.1161/01.HYP.0000202052.25238.68

45. O’Gallagher K, Borg Cardona S, Hill C, et al. Grapefruit juice enhances the systolic blood pressure-lowering effects of dietary nitrate-containing beetroot juice. Br J Clin Pharmacol. 2021;87(2):577-587. https://doi.org/10.1111/bcp.14420

46. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381. https://doi.org/10.1093/eurheartj/ehw106

47. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(SUPPL. 1):49-73. https://doi.org/10.1161/01.cir.0000437741.48606.98

48. Khanna NN, Jamthikar AD, Araki T, et al. Nonlinear model for the carotid artery disease 10-year risk prediction by fusing conventional cardiovascular factors to carotid ultrasound image phenotypes: A Japanese diabetes cohort study. Echocardiography. 2019;36(2):345-361. https://doi.org/10.1111/echo.14242

49. Blekkenhorst LC, Prince RL, Ward NC, et al. Development of a reference database for assessing dietary nitrate in vegetables. Mol Nutr Food Res. 2017;61(8):1-13. https://doi.org/10.1002/mnfr.201600982

50. Floyd CN, Shahed F, Ukah F, et al. Acute Blood Pressure-Lowering Effects of Nitrogen Dioxide Exposure from Domestic Gas Cooking via Elevation of Plasma Nitrite Concentration in Healthy Individuals. Circ Res. 2020;127(6):10-13. https://doi.org/10.1161/circresaha.120.316748